References
- 1. Adam R, Hoti E. Semin - Liver transplantation: the current situation. Liver Dis. 2009 Feb;29(1):3-18.
- 2. Befeler AS, Hayashi PH, Di Bisceglie AM. Liver transplantation for hepatocellular carcinoma. Gastroenterology. 2005;128:1752-1764.
- 3. Ringe B, Wittekind C, Bechstein WO, Bunzendahl H, Pichlmayr R. The role of liver transplantation in hepatobiliary malignancy: a retrospective analysis of 95 patients with particular regard to tumor stage and recurrence. Ann Surg. 1989;209:88-98.
- 4. Mazzaferro V, Regalia E, Doci R, et al. Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med. 1996;334:693-699.
- 5. Yao FY, Kinkhabwala M, LaBerge JM, et al. The impact of pre-operative loco-regional therapy on outcome after liver transplantation for hepatocellular carcinoma. Am J Transplant 2005;5:795-804.
- 6. Fehérvári I. Hepatocellular carcinoma and liver transplantation. Orv Hetil. 2010 Aug 8;151(32):1285-8. Hungarian.
- 7. Yoo HY, Patt CH, Geschwind JF, Thuluvath PJ. The outcome of liver transplantation in patients with hepatocellular carcinoma in the United States between 1988 and 2001: 5-year survival has improved signifi cantly with time. J. Clin. Oncol. 2003;21:4329-4335.
- 8. Hoti E, Adam R. Liver transplantation for primary and metastatic liver cancers. Transpl Int. 2008 Dec;21(12):1107-17.
- 9. Bellavance EC, Lumpkins KM, Mentha G, et al. Surgical management of early-stage hepatocellular carcinoma: resection or transplantation? J Gastrointest Surg. 2008 Oct;12(10):1699-708.
- 10. Fehérvári I. Májátültetés. Gastro Update 2009: 294 Hungarian.
- 11. Heckman JT, et al. Bridging locoregional therapy for hepatocellular carcinoma prior to liver transplantation. Ann. Surgical Oncology 2008. vol15(11):3169-3177.
- 12. Chapman WC, et al. Outcomes of neoadjuvant transarterial chemoembolization to downstage hepatocellular carcinoma before liver transplantation. Ann. Surgery 2008.vol 248(4):617-625.
- 13. Mazzaferro V, Chun YS, Poon RT, et al. Liver transplantation for hepatocellular carcinoma. Ann Surg Oncol. 2008 Apr;15(4):1001-7.
- 14. Herrero JI, Sangro B, Pardo F, et al. Liver transplantation in patients with hepatocellular carcinoma across Milan criteria. Liver Transpl. 2008 Mar;14(3):272-8.
- 15. Mazzaferro V, Llovet JM, Miceli R, et al; Metroticket Investigator Study Group. Predicting survival after liver transplantation in patients with hepatocellular carcinoma beyond the Milan criteria: a retrospective, exploratory analysis. Lancet Oncol. 2009 Jan;10(1):35-43.
- 16. Vivarelli M, Dazzi A, Cucchetti A, et al. Sirolimus in liver transplant recipients: a large single-center experience. Transplant Proc. 2010 Sep;42(7):2579-84.
- 17. Gomez-Martin C, Bustamante J, Castroagudin JF, et al. Effi cacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation. Liver Transpl. 2012 Jan;18(1):45-52.
- 18. Ito T, Takada Y, Ueda M, et al. Expansion of selection criteria for patients with hepatocellular carcinoma in living donor liver transplantation. Liver Transpl. 2007;13:1637-1644.